Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsCash from RestructuringChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyra Therapeutics (LYRA) Gains from Investment Securities (2021 - 2025)

Lyra Therapeutics (LYRA) has disclosed Gains from Investment Securities for 5 consecutive years, with $68558.0 as the latest value for Q3 2025.

  • On a quarterly basis, Gains from Investment Securities changed N/A to $68558.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $68558.0, a N/A change, with the full-year FY2024 number at $126255.0, down 97.79% from a year prior.
  • Gains from Investment Securities was $68558.0 for Q3 2025 at Lyra Therapeutics, up from $36296.0 in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $5.7 million in Q4 2023 to a low of $7000.0 in Q4 2021.
  • A 5-year average of $1.6 million and a median of $198485.5 in 2023 define the central range for Gains from Investment Securities.
  • Peak YoY movement for Gains from Investment Securities: surged 61490.47% in 2022, then crashed 99.8% in 2024.
  • Lyra Therapeutics' Gains from Investment Securities stood at $7000.0 in 2021, then soared by 61490.47% to $4.3 million in 2022, then skyrocketed by 32.44% to $5.7 million in 2023, then crashed by 97.79% to $126255.0 in 2024, then tumbled by 45.7% to $68558.0 in 2025.
  • Per Business Quant, the three most recent readings for LYRA's Gains from Investment Securities are $68558.0 (Q3 2025), $36296.0 (Q2 2025), and $4.5 million (Q1 2025).